鲁司帕西普

Luspatercept

Abstract

No information is available on the clinical use of luspatercept during breastfeeding. Because luspatercept is a large protein molecule with a molecular weight of 76,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, the manufacturer recommends that breastfeeding be discontinued during luspatercept therapy and for 3 months after the last dose.

摘要

关于哺乳期使用罗特西普的临床应用尚无可用信息。由于罗特西普是一种分子量为76,000道尔顿的大蛋白质分子，乳汁中的含量可能非常低。它也可能在婴儿胃肠道中被部分破坏，婴儿的吸收可能微乎其微。在获得更多数据之前，制造商建议在罗特西普治疗期间及最后一剂后3个月内停止母乳喂养。